Fraction of US outpatient treatment centers offer medication for opioid addiction

January 15, 2019

Despite the mounting death toll of America's opioid crisis, only a minority of facilities that treat substance use disorders offer patients buprenorphine, naltrexone or methadone--the three FDA-approved medications for the long-term management of opioid use disorder, according to a new study from researchers at the Johns Hopkins Bloomberg School of Public Health.

Notably, just six percent of medication-offering facilities offered all three FDA-approved medications to treat opioid use disorder, the study found. Ideally, facilities should be offering any of these three medications to best meet a patient's needs, as some patients may benefit more from methadone, others from buprenorphine and yet others from naloxone, extended release.

In the study, published in the January issue of Health Affairs, the researchers analyzed national survey data and found that from 2007 to 2016, the proportion of substance use disorder treatment facilities that offered any medication treatment for opioid use disorder increased from 20 to only 36 percent. In other words, as recently as 2016, when the opioid crisis was already deepening, nearly two-thirds of these facilities still did not offer such medications.

The analysis focused on the more than 10,000 facilities that offer outpatient services. Treatment facilities were significantly more likely to offer medication treatment in 2016 in states that have recently expanded Medicaid coverage, the researchers found.

"These results highlight the importance of Medicaid expansion in increasing the availability of medication treatment for opioid use disorder, though gaps in access remain widespread," says study lead author Ramin Mojtabai, MD, professor in the Department of Mental Health at the Bloomberg School.

The misuse of opioids in the U.S. began to expand rapidly in the late 1990s and has since escalated to epidemic proportions. The U.S. Centers for Disease Control and Prevention (CDC) has estimated that from 2002 to 2017 the number of fatal opioid overdoses annually rose from about 12,000 to over 47,000. Yet, studies suggest that relatively few people with opioid dependency receive any substance use disorder treatment--and fewer still get treatment with FDA-approved medications.

To determine the reasons for this lack of treatment, Mojtabai and colleagues evaluated data gathered from 2007 to 2016 in yearly surveys of known treatment facilities by the Substance Abuse and Mental Health Services Administration (SAMHSA).

A key finding was that only 36.1 percent of these facilities offered any medication treatment for opioid use disorder in 2016, up from 20.0 percent in 2007. About 70 percent of these medication-offering facilities offered buprenorphine, 57.6 percent offered extended-release naltrexone and 28.7 percent offered methadone.

In general, there was wide variation in treatment available among states. Rhode Island, New York and Vermont topped the rankings with more than 70 percent of the facilities in each state offering one of the three FDA-approved medications. Hawaii (8.6 percent), Arkansas (14.1 percent) and Idaho (16.8 percent) had the lowest proportions of treatment facilities offering any FDA-approved medication. States with a higher prevalence of heroin use and more opioid overdose deaths tended to have treatment facilities offering medication treatment.

In recent years, 37 states have expanded Medicaid to low-income groups under the Affordable Care Act. Mojtabai and colleagues found that substance use disorder treatment facilities located in these Medicaid expansion states were about 21 percent more likely to offer medication treatment--and 89 percent more likely if the facility had a policy to accept Medicaid insurance.

"These results are likely related to the more robust coverage of medication treatment under Medicaid programs in expansion states," Mojtabai says.

Even so, he notes that many low-income people still lack ready access to treatment facilities accepting reimbursement through state Medicaid programs.

Mojtabai and colleagues suggest that while continued Medicaid expansion and other changes to health insurance might continue to improve the situation in the long run, currently state governments have the power to expand medication treatment availability more rapidly.

"States get block grants from SAMHSA for substance use and mental health facilities, and they could require facilities that receive these payments to offer medication treatment for opioid use disorder as a condition of receiving block grant funding," Mojtabai says.

"Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities" was written by Ramin Mojtabai, Christine Mauro, Melanie Wall, Colleen Barry, and Mark Olfson.
-end-
Funding was provided by the National Institute on Drug Abuse (R01DA039137).

Johns Hopkins University Bloomberg School of Public Health

Related Mental Health Articles from Brightsurf:

Mental health strained by disaster
A new study found that suicide rates increase during all types of disasters -- including severe storms, floods, hurricanes and ice storms -- with the largest overall increase occurring two years after a disaster.

The mental health impact of pandemics for front line health care staff
New research shows the impact that pandemics have on the mental health of front-line health care staff.

World Mental Health Day -- CACTUS releases report of largest researcher mental health survey
On the occasion of 'World Mental Health Day' 2020, CACTUS, a global scientific communications company, has released a global survey on mental health, wellbeing and fulfilment in academia.

Mental illness, mental health care use among police officers
A survey study of Texas police officers examines how common mental illness and mental health care use are in a large urban department.

COVID-19 outbreak and mental health
The use of online platforms to guide effective consumption of information, facilitate social support and continue mental health care delivery during the COVID-19 pandemic is discussed in this Viewpoint.

COVID-19 may have consequences for mental health
The COVID-19 pandemic appears to be adversely affecting mental health among hospitalised patients, the healthcare professionals treating them and the general population.

Mental health outcomes among health care workers during COVID-19 pandemic in Italy
Symptoms of posttraumatic stress disorder, depression, anxiety and insomnia among health care workers in Italy during the COVID-19 pandemic are reported in this observational study.

Mental ill health 'substantial health concern' among police, finds international study
Mental health issues among police officers are a 'substantial health concern,' with around 1 in 4 potentially drinking at hazardous levels and around 1 in 7 meeting the criteria for post traumatic stress disorder and depression, finds a pooled data analysis of the available international evidence, published online in Occupational & Environmental Medicine.

Examining health insurance nondiscrimination policies with mental health among gender minority individuals
A large private health insurance database was used to examine the association between between health insurance nondiscrimination policies and mental health outcomes for gender minority individuals.

Mental health care for adolescents
Researchers examined changes over time in the kinds of mental health problems for which adolescents in the United States received care and where they got that care in this survey study with findings that should be interpreted within the context of several limitations including self-reported information.

Read More: Mental Health News and Mental Health Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.